RoslinCT

Opportunity to create a scaled global leader at the forefront of cell therapy manufacturing, supporting Pharma and Biotech companies from development phase through to commercial manufacturing.

Investment into diversifying the business beyond non-viral gene modified cell therapies to include viral gene modification therapies and other cell types with a view to doubling Roslin’s addressable market.

Significant investment into corporate infrastructure and operations including finance, commercial and IT infrastructure, leveraging GHO’s portfolio and advisor network.

Organic capex initiatives including the construction of a greenfield site in the Edinburgh area to more than quadruple Roslin’s development and manufacturing capacity.

Developing a focused commercial go-to-market strategy to grow existing client base and unlock significant white space in the market.

Continuation of build-out, expanding blue chip client base through international expansion with the US considered a key market for cell therapy biotechs.